our local BBC midlands news supporting @TheBHF programme to make sure women get better heart attack care https://t.co/dP4dvJRqpK @cpgale3 @SWBHnhs @ICVS_UoB @CardiologySWBH

Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial)

From a new @TheLancet article today entitled "Health care in the USA: money has become the mission" https://t.co/jAjrsgJ5Zn

Post-hoc analysis of SYNERGY-NASH trial reveals key insights on #tirzepatide in #MASH patients ✅ MASH resolution linked to greater weight loss (-16% vs -7%) ✅ Fibrosis improvement associated with better glycemic control ✅ Liver fat normalization was key mediator of both

The largest multinational cohort study conducted to date investigated different classes of antihypertensive drugs and the risk of incident dementia. Conclusion: physicians & patients should consider the reduced risk of all-cause dementia and Vascular Dementia with ARB compared

⬆️Lp(a) levels are independently associated with subclinical coronary atherosclerosis in ageing endurance athletes and healthy controls even with low conventional CV risk. 👉 Highlights the value of Lp(a) for risk stratification in low-risk populations. https://t.co/KNwiPpOCQK

Santorini Italy. 55-% use of combo Lipid lowering Tx mostly statins plus ezetimibe with 37 and 44% of pts achieving risk based LDL -C goals. Next iteration of most guidelines like BP and DM should consider FDC as SoC https://t.co/i4oeIJoiT7

We’re excited to see our Alzheimer’s disease biomarker data from a prespecified substudy  in our BROADWAY clinical trial has been peer-reviewed and published in @jpreventionalz1. 🔓 Read the open access article: https://t.co/JLv6GnFDCT

Statin therapy during pregnancy. Read more in the @EHJ at https://t.co/DsdR8aBFMO #PregnancyHealth #StatinTherapy #MaternalHealth #PregnancyCare @ESCardio @ESC_Journals

Sunday afternoon catch up with Consultant Cardiologist Colleagues post ward round and primary angioplasties @MidlandMetUH 24/7 but with coffee breaks @CardiologySWBH @SWBHnhs

Statin efficacy to decrease #MACE depends on #CAD phenotypes and increases with the extent and severity of disease and in the presence of high-risk plaques. Patients without CAD have no benefit from statin therapy regarding MACE. https://t.co/OUpvgkgOBv #JACCIMG #cvCAD

Great to see another great Cardiology Quiz of the Day on MedShr from @drahmedmohsen85 Check it out at https://t.co/UEcUedakhy @ShrillaB @cpgale3 @aayshacader @mirvatalasnag @TCTMD @mmamas1973 @DrDerekConnolly @medshronline @JanisKPereira @sophiakhattak @samia_tasneem1

Using combination lipid-lowering therapy in high-risk patients instead of statin monotherapy could prevent 330,000 deaths globally each year, according to a recent meta-analysis published in Mayo Clinic Proceedings. The findings, drawn from data on over 108,000 patients,

💔 Triple therapy in HFmrEF/HFpEF — potential long-term gains @mvaduganathan et al 📊 Cross-trial analysis (DELIVER, FINEARTS-HF, PARAGON-HF) • SGLT2i + nsMRA → ↓ CV death or 1st HF event by 31% (HR 0.69) • SGLT2i + nsMRA + ARNI → ↓ risk by 39% (HR 0.61; LVEF <60%) •

🔥 Incretin therapies & liver outcomes in T2 diabetes Real-world EHR study (150M+ pateints): 📉 Tirzepatide↓ risk of major adverse liver outcomes (MALO) by 47%(HR 0.53) 📉 Semaglutide↓ risk by 19% (HR 0.81) ⚪️ Liraglutide - no significant benefit ➡️ Benefit driven by ↓

The evolution of plasma cholesterol: Direct utility or a ‘‘spandrel” of hepatic lipid metabolism? 🧬 LDL: Evolution’s Beautiful Mistake What if “LDL” was never meant to exist? ☝️LDL is not a product of evolutionary design, but an accident of hepatic lipid metabolism — a

is this the future of drug trials in our war against atherosclerosis? non invasive testing of how obiceptrapib reduces coronary inflammation and plaque volume https://t.co/1CTmNmdt2r

Algorithm for #resmetirom treatment from the Global Consensus Recommendations for MASLD and MASH. https://t.co/O3OqWGNvhB

Obesity in older adults is rising, and semaglutide & tirzepatide can bring significant weight loss and better heart, liver, and kidney health. Risks for older adults are muscle loss and functional decline. Policy must prioritize coverage + clinical trials for seniors to ensure

Today is World Thrombosis Day — a global reminder to raise awareness about blood clots and their prevention: #WorldThrombosisDay @LHCHFT @LivHPartners https://t.co/jv1C5CQoUT

Multi-society consensus guidelines have stated there is no need to routinely hold GLP-1 prior to procedures. Here is another real-world analysis again showing the lack of any increased peri-procedure adverse events.